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From the Editor 
 
Seeking Middle Ground 
____________________________________________________________ 
 
As a medical educator and practicing primary care general internist at our academic 
medical center, I have probably attended literally hundreds of pharmaceutical 
company-sponsored lunches and grand rounds over the course of the last 14 years. 
No doubt, I have received scores of pens and pads branded with the names of 
dozens of different proprietary pharmaceutical products. I have probably collected 
hundreds of similar items walking the exhibit halls at major national medical 
meetings over a dozen years.  
 
As a result of my behavior, many current observers would say that I have an 
inherent conflict of interest vis-à-vis the pharmaceutical industry and my work as a 
clinician. Evidence does support the fact that the pharmaceutical industry has 
contributed more than 60 percent of the total national support for continuing medical 
education (CME) on an annual basis.1 Does this make all of CME suspect? I would 
like to explore this perception of a conflict of interest and seek middle ground 
amongst the cacophony of shrill voices demonstrating their tightly held beliefs across 
the spectrum of viewpoints in this arena. 
 
Our current environment is poisoned by a slew of recent adverse publicity with 
regard to these perceived conflict of interest issues. The Boston Globe ran a front-
page story this past summer detailing the recent investigations by the U.S. 
Attorney’s Office in Boston.2 These federal investigators are sending subpoenas to 
top academic medical centers, and elsewhere in the country, for records about their 
relationships with drug makers as part of a widespread crackdown on pharmaceutical 
company marketing practices. Federal prosecutors, according to the Globe, are 
looking into whether drug companies have been using these grants, in some cases, 
to try to influence doctors at leading hospitals to prescribe their medications to 
patients.  If true, such behavior would be illegal under federal anti-kickback laws and 
may play a role in skyrocketing prescription drug costs.2
This Boston Globe story was then amplified in the medical press with a detailed piece 
in Modern Healthcare.3 Nationally prominent physician leaders such as Jordan Cohen, 
MD, the president of the Association of American Medical Colleges (AAMC), and 
others, were asked to give their views. Predictably, and appropriately, the AAMC 
supports its longstanding view that there needs to be a very careful arms-length 
relationship, if any relationship, between academic medical centers and the 
pharmaceutical industry. At nearly the same time, the popular news program 
Dateline NBC featured a summer headline-getting segment entitled “Drug Giant 
Accused of False Claims.”4 In this July 2003 story, a scientist from Warner 
Lambert confessed, “It was my responsibility to leverage the trust that physicians 
had with pharmaceutical companies to corrupt the relationship between the physician 
and the patient.” He specifically admitted to participating in activities promoting off-
label use of certain neurologic medications. 
 
Contemporaneously, Dana and colleagues, writing in the Journal of the American 
Medical Association, cite extensive social science research supporting their 
contention that individuals, even professionals, are often unable to avoid bias even 
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when it is in their best interest to do so.5 They contend that physicians will deny and 
succumb to bias, even when explicitly instructed about it, which suggests to them 
that self-serving bias is unconscious. Furthermore, they believe that even small gifts, 
those in keeping with current guidelines published by the Accreditation Council on 
Continuing Medical Education (ACCME), can subtly bias how arguments are 
evaluated, and they can be surprisingly influential. They call for an outright ban on 
all gifts to physicians regardless of size or scope. Even some of our most influential 
leaders have repeatedly called for a complete separation between the marketing and 
educational functions of large pharmaceutical companies.6 Is there a middle ground 
in this controversy, and what constructive efforts might we undertake to promote 
that middle ground? 
 
Recognizing the scope and depth of this national .conflict of interest. debate, I am 
happy to report that Jefferson Medical College has created an operational framework 
to deal with this dilemma by forming a groundbreaking new entity aptly named JIAC 
-- the Jefferson Industry Advisory Council. Under the leadership of Dr. Geno Merli, 
the Ludwig Kind Professor of Medicine and Senior Associate Dean for CME, Dr. 
Richard Wender, the Alumni Professor and Chairman of the Department of Family 
Medicine and Chairman of the Jefferson Medical College CME Committee, and the 
Office of Health Policy and Clinical Outcomes, the JIAC has completed two meetings 
over the last year. The goal of JIAC is to serve as a forum in which representatives 
from across Thomas Jefferson University can meet with multiple pharmaceutical 
companies and explore ways we might work together more effectively within current 
environmental constraints.  
 
Ultimately, there is congruence in our thinking as the industry and JMC wish to 
create outstanding educational programs for all of our clinicians. JIAC has called for 
multi- and inter-disciplinary educational programming, the reduction of medical 
error, and the maintenance of a proper balance in the content of all professional 
educational programming on our campus. Without an appropriate dialog, there can 
be no progress. What have we learned from our JIAC experience thus far? 
 
Surprisingly, we have learned that representatives from more than 50 different 
pharmaceutical companies have urged us to work together with them to more clearly 
delineate our educational goals and to explicitly separate those goals from the 
marketing function of the industry. Industry representatives are deeply interested in 
measuring a return on investment (ROI) for their support of CME. This ROI is not 
linked to an increase in the number of prescriptions written but, rather, new tools 
and techniques to measure the outcomes of educational programming. Frankly, this 
is very much in line with recent curriculum requirements from the Accreditation 
Council for Graduation Medical Education (ACGME), which have been described in 
detail in this space previously (“ACGME Competencies: The Curricular Challenge,” 
Health Policy Newsletter editorial, December 2002). Industry representatives would 
like us to make more effective use of the Internet as a training tool and offered 
detailed suggestions as to how we might operationalize such programs. They urged 
us to create a repository of enduring CME materials easily accessible and not linked 
to any one sponsor. They invited us to participate in the actual training of the field 
representatives in order that they may better understand the role of certain 
specialists and the team approach to patient care. They challenged us to provide 
better research comparing the economic ramifications of new technologies. Detailed 
summaries of the JIAC proceedings are available through the JMC Office of 
Continuing Medical Education. 
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In the final analysis, I believe that some of the recent media attention to these 
perceived conflicts of interest regarding our relationship with the pharmaceutical 
industry comes as a toxic byproduct of other corporate malfeasance in the likes of 
Enron, WorldCom, and others. These concerns transcend the United States, as there 
is considerable international interest in comparable issues well described in a recent 
article in the British Medical Journal.7
Personally, I do not believe that we should cancel all pharmaceutical-sponsored 
activities within medical schools or even prohibit the distribution of pens and pads! I 
am committed to finding that middle ground where we can work together to better 
understand how new agents diffuse into practice. I support educational research to 
find better outcome measures of our work together. Simply cataloging a change in 
physician attitudes or tracking script-writing behavior is insufficient for the 21st
century. While we may be loath to admit it, the pharmaceutical industry has decades 
of experience in influencing and changing physician behavior. Perhaps there is 
something we can harness here that will serve our own needs with regard to the 
standardization of care, quality measurement and improvement, and error reduction. 
The publication of additional weighty “Codes of Conduct” are important, but 
additional pronouncements will not provide us with the operational framework, like 
JIAC, to move forward. Provocative? Surely. Pragmatic? I hope so.  As usual, I am 
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